On December 27, the US Food and Drug Administration approved tislelizumab-jsgr in combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1.

For more information, read the BeiGene press release.

Posted on 1/2/2025